Table 2.
Ratios and Summary Statistics for PVR and the PVRI in Patients Administered Macitentan 10 mg (n=9)
| Ratio of PVR at Week 16 to baselineA (%) | |
| Mean±SD | 71.9±34.3 |
| Median | 66.0 |
| IQR | 51.0, 81.0 |
| Minimum-maximum | 21–138 |
| Geometric mean (CV%)B | 64.1 (58.1) |
| 95% CIB | 42.3, 97.0 |
| PVR (dyn·s/cm5) | |
| Baseline | |
| Mean±SD | 796.8±421.9 |
| Median | 671.0 |
| IQR | 627.0, 769.0 |
| Week 16 | |
| Mean±SD | 615.4±446.9 |
| Median | 441.0 |
| IQR | 318.0, 769.0 |
| Change from baseline at Week 16 | |
| Mean±SD | −181.4±243.9 |
| Median | −230.0 |
| IQR | −313.0, −147.0 |
| PVRI (dyn·s·m2/cm5) | |
| Baseline | |
| Mean±SD | 1,155.2±532.2 |
| Median | 952.4 |
| IQR | 900.0, 1,111.1 |
| Week 16 | |
| Mean±SD | 874.6±628.1 |
| Median | 577.8 |
| IQR | 471.8, 1,173.3 |
| Change from baseline at Week 16 | |
| Mean±SD | −280.6±366.0 |
| Median | −322.2 |
| IQR | −523.1, −187.2 |
For PVR and the PVR index (PVRI), data are expressed as mean±SD. AThe ratio was calculated as (PVR at Week 16/PVR at baseline) × 100. BThe geometric mean, coefficients of variation (CV), and 95% confidence intervals (CI) were estimated for the ratio of PVR at Week 16 to that at baseline as a post hoc analysis. IQR, interquartile range; PVR, pulmonary vascular resistance.